251 related articles for article (PubMed ID: 16710042)
1. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Panasci LC
J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
[No Abstract] [Full Text] [Related]
2. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
3. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
Henry NL; Hayes DF
J Clin Oncol; 2007 Jun; 25(18):2501-3. PubMed ID: 17577024
[No Abstract] [Full Text] [Related]
4. [Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
Garin AM; Dmitrieva NV; Vyshinskaia GV; Lichintser MR
Vopr Onkol; 1987; 33(11):13-7. PubMed ID: 3686916
[TBL] [Abstract][Full Text] [Related]
5. [A randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients].
Sack H
Strahlenther Onkol; 1995 Jun; 171(6):360-1. PubMed ID: 7597623
[No Abstract] [Full Text] [Related]
6. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
Albain KS
J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631
[No Abstract] [Full Text] [Related]
8. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials referral resource. Adjuvant therapy of breast cancer.
Cheson BD
Oncology (Williston Park); 1989 Jun; 3(6):70-1, 74-5, 78. PubMed ID: 2534915
[No Abstract] [Full Text] [Related]
10. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
[TBL] [Abstract][Full Text] [Related]
11. Evolving concepts in the systemic adjuvant treatment of breast cancer.
Bonadonna G
Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
[No Abstract] [Full Text] [Related]
12. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
13. Late cardiac effects of adjuvant radiotherapy and chemotherapy in early breast cancer.
Coccaro M; Gallucci G
J Clin Oncol; 2008 Jul; 26(19):3288; author reply 3289. PubMed ID: 18591567
[No Abstract] [Full Text] [Related]
14. [A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
Shiba E; Koyama H; Sasaki Y; Iwanaga T; Terasawa T; Wada A
Gan No Rinsho; 1985 Sep; 31(11):1439-44. PubMed ID: 3934423
[TBL] [Abstract][Full Text] [Related]
15. [Bone metastasis of breast cancer. Apropos of a series of 50 cases].
Vincent-Joyeux F; Bontoux D; Alcalay M; Daban A; Vincent D
Sem Hop; 1982 Dec; 58(48):2827-31. PubMed ID: 6302849
[TBL] [Abstract][Full Text] [Related]
16. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
17. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor status of breast cancer metastases.
Branković-Magić M; Janković R; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
J Cancer Res Clin Oncol; 2002 Jan; 128(1):55-60. PubMed ID: 11862473
[TBL] [Abstract][Full Text] [Related]
19. [Survival and factors related to the survival of recurrent breast cancer patients--a study with quantification theory].
Murayama Y
Gan No Rinsho; 1983 Apr; 29(4):A-20, 311-4. PubMed ID: 6687908
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
